Abstract:Background: Pathological cardiac hypertrophy induced by stresses such as aging and neurohumoral activation is an independent risk factor for heart failure and is considered a target for the treatment of heart failure. However, the mechanisms underlying pathological cardiac hypertrophy remain largely unknown. We aimed to investigate the roles of SIRT2 in aging-related and angiotensin II (Ang II)–induced pathological cardiac hypertrophy. Methods: Male C57BL/6J wild-type and Sirt2 knockout mice were subjected to the investigation of aging-related cardiac hypertrophy. Cardiac hypertrophy was also induced by Ang II (1.3 mg/kg/d for 4 weeks) in male C57BL/6J Sirt2 knockout mice, cardiac-specific SIRT2 transgenic ( SIRT2 -Tg) mice, and their respective littermates (8 to ≈12 weeks old). Metformin (200 mg/kg/d) was used to treat wild-type and Sirt2 knockout mice infused with Ang II. Cardiac hypertrophy, fibrosis, and cardiac function were examined in these mice. Results: SIRT2 protein expression levels were downregulated in hypertrophic hearts from mice. Sirt2 knockout markedly exaggerated cardiac hypertrophy and fibrosis and decreased cardiac ejection fraction and fractional shortening in aged (24-month-old) mice and Ang II–infused mice. Conversely, cardiac-specific SIRT2 overexpression protected the hearts against Ang II–induced cardiac hypertrophy and fibrosis and rescued cardiac function. Mechanistically, SIRT2 maintained the activity of AMP-activated protein kinase (AMPK) in aged and Ang II–induced hypertrophic hearts in vivo as well as in cardiomyocytes in vitro. We identified the liver kinase B1 (LKB1), the major upstream kinase of AMPK, as the direct target of SIRT2. SIRT2 bound to LKB1 and deacetylated it at lysine 48, which promoted the phosphorylation of LKB1 and the subsequent activation of LKB1-AMPK signaling. Remarkably, the loss of SIRT2 blunted the response of AMPK to metformin treatment in mice infused with Ang II and repressed the metformin-mediated reduction of cardiac hypertrophy and protection of cardiac function. Conclusions: SIRT2 promotes AMPK activation by deacetylating the kinase LKB1. Loss of SIRT2 reduces AMPK activation, promotes aging-related and Ang II–induced cardiac hypertrophy, and blunts metformin-mediated cardioprotective effects. These findings indicate that SIRT2 will be a potential target for therapeutic interventions in aging- and stress-induced cardiac hypertrophy.

The role of SIRT2 in vascular‐related and heart‐related diseases: A review

Roles of SIRT3 in Heart Failure: from Bench to Bedside.

SIRT2 inhibition protects against cardiac hypertrophy and heart failure

The role of sirtuins in cardiac disease

Sirtuin 2 deficiency aggravates ageing-induced vascular remodelling in humans and mice

Research progress of sirtuins in renal and cardiovascular diseases.

Multiple Roles of SIRT2 in Regulating Physiological and Pathological Signal Transduction

Abstract 10153: SIRT1 Activation Restores Cardioprotection in the Aged Heart Against Ischemia/Reperfusion Injury

The protective role of Sirt1 in vascular tissue: its relationship to vascular aging and atherosclerosis

Sirtuins family as a target in endothelial cell dysfunction: implications for vascular ageing

The Role of Sirtuin1 in Regulating Endothelial Function, Arterial Remodeling and Vascular Aging

SIRT3: A New Regulator of Cardiovascular Diseases

Emerging role of SIRT3 in endothelial metabolism, angiogenesis, and cardiovascular disease

The role of Sirtuin 2 in liver - An extensive and complex biological process

SIRT1 in vascular related diseases:its progress

The Role of Mammalian Sirtuin 6 in Cardiovascular Diseases and Diabetes Mellitus

SIRT2 Acts As a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.

Sirt1 Inhibits Oxidative Stress in Vascular Endothelial Cells

Dual-edged role of SIRT1 in energy metabolism and cardiovascular disease

A pharmacological review on SIRT 1 and SIRT 2 proteins, activators, and inhibitors: Call for further research

Caloric restriction, Sirtuins, and cardiovascular diseases